Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG-102-12C in Advanced Hepatocellular Carcinoma
NCT07039201Recruiting
- Sponsor
- Zhejiang University
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of CG-102-12C in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Primary endpoints: Dose Limiting Toxicity at 28 days and Treatment-Emergent Adverse Events at 24 months. Started Jun 2025; status: recruiting.
02
Drugs
CG-102-12C
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07039201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07039201.